PRIMARY MEMBRANOUS NEPHROPATHY
Clinical trials for PRIMARY MEMBRANOUS NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEMBRANOUS NEPHROPATHY trials appear
Sign up with your email to follow new studies for PRIMARY MEMBRANOUS NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can engineered immune cells tackle a tough kidney disease?
⭐️ CURE ⭐️ Not yet recruitingThis trial is testing an experimental therapy called FKC289 for people with a type of kidney disease called primary membranous nephropathy that has come back or not responded to standard treatment. FKC289 uses the patient's own immune cells, which are modified in the lab to recog…
Matched conditions: PRIMARY MEMBRANOUS NEPHROPATHY
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd. • Aim: ⭐️ CURE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
Can engineered immune cells tame autoimmune kidney disease?
Disease control Not yet recruitingThis early-stage trial is testing whether a single infusion of universal STAR-T cells—a type of engineered immune cell that targets both CD19 and BCMA—can safely and effectively treat two autoimmune kidney diseases: IgA nephropathy and primary membranous nephropathy. The study wi…
Matched conditions: PRIMARY MEMBRANOUS NEPHROPATHY
Phase: NA • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a gene-silencing drug calm overactive complement in kidney disease?
Disease control Not yet recruitingThis phase II trial tests an experimental drug called QLS7305 in people with several kidney diseases driven by overactivation of the complement system, a part of the immune system. The drug is a small interfering RNA (siRNA) designed to reduce production of complement protein C3,…
Matched conditions: PRIMARY MEMBRANOUS NEPHROPATHY
Phase: PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New antibody drug aims to tame Hard-to-Treat kidney disease
Disease control Not yet recruitingThis early-stage trial tests a new drug called YK012 in 66 adults with a severe form of kidney disease called primary membranous nephropathy that has not responded to standard treatments. YK012 is a bispecific antibody designed to reduce the immune system's attack on the kidneys.…
Matched conditions: PRIMARY MEMBRANOUS NEPHROPATHY
Phase: PHASE1 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC